Catalyst Pharmaceutical Partners (CPRX) 3.36 $CPRX
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering
GlobeNewswire - Mon Feb 09, 9:10AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 11,500,000 shares of its common stock in the offering, which includes 1,500,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $3.25 per share, and the net proceeds from the sale of the shares is expected to be approximately $34.7 million. Piper Jaffray & Co. acted as the sole lead book-running manager and SunTrust Robinson Humphrey acted as the passive book-running manager with respect to this offering. Further, Roth Capital Partners and H.C. Wainwright & Co. acted as the lead co-manager and co-manager, respectively.
CPRX: 3.36 (-0.10)
Catalyst prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:34AM CST
CPRX: 3.36 (-0.10)
Premarket Gainers / Losers as if 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:13AM CST
SPLS: 16.86 (-0.22), EXXI: 4.00 (+0.42), NES: 3.52 (+0.13), MYGN: 34.03 (+0.40), CALX: 8.65 (-0.03), OIBR: 2.49 (+0.34), SNE: 27.30 (+0.19), SDRL: 12.32 (-0.70), RL: 135.20 (-0.60), SJM: 113.89 (+1.50), GENE: 8.04 (+1.90), GDP: 3.58 (+0.29), CPRX: 3.36 (-0.10), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CMG: 674.89 (+4.60), VGGL: 1.77 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ENTR: 2.92 (unch)
Catalyst Pharmaceutical Partners, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 8:10AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at an offering price of $3.25 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.
CPRX: 3.36 (-0.10)
Catalyst Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:02PM CST
CPRX: 3.36 (-0.10)
Catalyst Pharmaceutical Partners, Inc. Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:40PM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced today that it intends to offer shares of its common stock in a public offering. Catalyst also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Catalyst plans to use the net proceeds from the offering (i) to pay milestone payments due on final approval of an NDA for Firdapse(TM); (ii) to pay pre-commercialization and other expenses required to launch Firdapse(TM); (iii) to fund future clinical studies of Firdapse(TM) for other indications, to the extent that such additional studies are required; (iv) to fund future clinical and nonclinical studies of CPP-115; and (v) for general corporate purposes.
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Feb 02, 9:05AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced it has held a productive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding Firdapse(TM) for the treatment of LEMS. Based on this meeting, Catalyst believes that its Phase 3 clinical program will provide acceptable support for submission of an NDA for Firdapse(TM) for LEMS. The Company plans to complete a full NDA submission during the 3rd quarter of 2015. Catalyst will confirm the overall regulatory path forward upon receipt of formal meeting minutes from the FDA in the coming weeks and will provide a further update at that time.
CPRX: 3.36 (-0.10)
5 Stocks Under $10 Making Big Moves: Rex Energy, Corinthian Colleges and More
at The Street - Fri Jan 23, 12:09PM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
LGCY: 13.35 (+0.51), TXMD: 4.70 (-0.09), CPRX: 3.36 (-0.10), REXX: 5.08 (+0.13), COCO: 0.02 (-0.01)
5 Stocks Insiders Are Snapping Up: Biglari, Catalyst Pharma and More
at The Street - Thu Jan 15, 11:01AM CST
Insiders usually buy their own shares because they think the stock is a bargain and has tremendous upside.
BH: 416.41 (-1.55), AFAM: 30.88 (+0.37), CPRX: 3.36 (-0.10), RM: 15.88 (+0.96), OAS: 16.84 (-0.03)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Catalyst Pharmaceuticals Provides an Update of 2015 Goals for Its Product Portfolio
GlobeNewswire - Mon Jan 12, 8:16AM CST
Pre-NDA Meeting with the FDA
CPRX: 3.36 (-0.10)
InsiderInsights.com Daily Round Up 1/8/15: CPRX, HCOM, RPXC, ARIS
InsiderInsights - at Seeking Alpha - Sat Jan 10, 2:07AM CST
RH: 86.77 (-1.55), MNST: 117.74 (-1.77), HCOM: 26.76 (-0.10), SPE: 15.27 (+0.02), PGEM: 13.79 (+0.24), ARIS: 3.63 (-0.01), FUND: 7.47 (+0.05), RPXC: 13.94 (+0.42), CMC: 15.40 (+0.37), LNKD: 269.00 (+1.83), PFPT: 55.97 (+0.38), CPRX: 3.36 (-0.10), REN: 1.14 (unch), NERV: 4.68 (+0.09), NLNK: 38.84 (+1.51), CPLA: 65.23 (-1.37), WYY: 1.50 (+0.02), ESP: 29.25 (+2.53)
New commercial chief at Catalyst Pharma
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:03PM CST
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
GlobeNewswire - Mon Jan 05, 7:25AM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that David D. Muth, currently Executive Vice President, Corporate Development of Catalyst, has been promoted to the newly created position of Executive Vice President, Chief Commercial Officer, effective January 1, 2015. Mr. Muth will continue to report to Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst.
CPRX: 3.36 (-0.10)
OTC Daily Alert Stock Watch - Catalyst Pharmaceuticals (NASDAQ: CPRX)
WorldStockWire - Mon Dec 29, 3:15PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CPRX: 3.36 (-0.10)
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Catalyst Pharmaceutical Partners, Inc. -- CPRX
GlobeNewswire - Thu Dec 18, 7:10AM CST
The Rosen Law Firm, P.A. announces that the United States District Court Southern District of Florida has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX):
CPRX: 3.36 (-0.10)
Catalyst Pharma founder passes
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:54AM CST
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals expresses sympathy on passing of co-founder and director Dr Hubert E. Huckel
M2 - Wed Dec 17, 7:59AM CST
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday that its co-founder and director Dr Hubert E. Huckel, MD has died.
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founder and Director
GlobeNewswire - Tue Dec 16, 2:45PM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced with great sadness the loss of Co-Founder and director, Hubert E. Huckel, M.D. Dr. Huckel, a founding shareholder and director of Catalyst since its formation in January 2002, passed away on December 13, 2014.
CPRX: 3.36 (-0.10)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 37.22 (+0.27), TNXP: 5.78 (-0.02), MRNS: 10.94 (-0.06), CPRX: 3.36 (-0.10), VNDA: 12.37 (unch), ITCI: 24.53 (+2.45), OMER: 20.63 (+0.13)
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering
GlobeNewswire - Mon Feb 09, 9:10AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 11,500,000 shares of its common stock in the offering, which includes 1,500,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $3.25 per share, and the net proceeds from the sale of the shares is expected to be approximately $34.7 million. Piper Jaffray & Co. acted as the sole lead book-running manager and SunTrust Robinson Humphrey acted as the passive book-running manager with respect to this offering. Further, Roth Capital Partners and H.C. Wainwright & Co. acted as the lead co-manager and co-manager, respectively.
CPRX: 3.36 (-0.10)
Catalyst prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:34AM CST
CPRX: 3.36 (-0.10)
Premarket Gainers / Losers as if 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:13AM CST
SPLS: 16.86 (-0.22), EXXI: 4.00 (+0.42), NES: 3.52 (+0.13), MYGN: 34.03 (+0.40), CALX: 8.65 (-0.03), OIBR: 2.49 (+0.34), SNE: 27.30 (+0.19), SDRL: 12.32 (-0.70), RL: 135.20 (-0.60), SJM: 113.89 (+1.50), GENE: 8.04 (+1.90), GDP: 3.58 (+0.29), CPRX: 3.36 (-0.10), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CMG: 674.89 (+4.60), VGGL: 1.77 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ENTR: 2.92 (unch)
Catalyst Pharmaceutical Partners, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 8:10AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at an offering price of $3.25 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.
CPRX: 3.36 (-0.10)
Catalyst Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:02PM CST
CPRX: 3.36 (-0.10)
Catalyst Pharmaceutical Partners, Inc. Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:40PM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced today that it intends to offer shares of its common stock in a public offering. Catalyst also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Catalyst plans to use the net proceeds from the offering (i) to pay milestone payments due on final approval of an NDA for Firdapse(TM); (ii) to pay pre-commercialization and other expenses required to launch Firdapse(TM); (iii) to fund future clinical studies of Firdapse(TM) for other indications, to the extent that such additional studies are required; (iv) to fund future clinical and nonclinical studies of CPP-115; and (v) for general corporate purposes.
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Feb 02, 9:05AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced it has held a productive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding Firdapse(TM) for the treatment of LEMS. Based on this meeting, Catalyst believes that its Phase 3 clinical program will provide acceptable support for submission of an NDA for Firdapse(TM) for LEMS. The Company plans to complete a full NDA submission during the 3rd quarter of 2015. Catalyst will confirm the overall regulatory path forward upon receipt of formal meeting minutes from the FDA in the coming weeks and will provide a further update at that time.
CPRX: 3.36 (-0.10)
5 Stocks Under $10 Making Big Moves: Rex Energy, Corinthian Colleges and More
at The Street - Fri Jan 23, 12:09PM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
LGCY: 13.35 (+0.51), TXMD: 4.70 (-0.09), CPRX: 3.36 (-0.10), REXX: 5.08 (+0.13), COCO: 0.02 (-0.01)
5 Stocks Insiders Are Snapping Up: Biglari, Catalyst Pharma and More
at The Street - Thu Jan 15, 11:01AM CST
Insiders usually buy their own shares because they think the stock is a bargain and has tremendous upside.
BH: 416.41 (-1.55), AFAM: 30.88 (+0.37), CPRX: 3.36 (-0.10), RM: 15.88 (+0.96), OAS: 16.84 (-0.03)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Catalyst Pharmaceuticals Provides an Update of 2015 Goals for Its Product Portfolio
GlobeNewswire - Mon Jan 12, 8:16AM CST
Pre-NDA Meeting with the FDA
CPRX: 3.36 (-0.10)
InsiderInsights.com Daily Round Up 1/8/15: CPRX, HCOM, RPXC, ARIS
InsiderInsights - at Seeking Alpha - Sat Jan 10, 2:07AM CST
RH: 86.77 (-1.55), MNST: 117.74 (-1.77), HCOM: 26.76 (-0.10), SPE: 15.27 (+0.02), PGEM: 13.79 (+0.24), ARIS: 3.63 (-0.01), FUND: 7.47 (+0.05), RPXC: 13.94 (+0.42), CMC: 15.40 (+0.37), LNKD: 269.00 (+1.83), PFPT: 55.97 (+0.38), CPRX: 3.36 (-0.10), REN: 1.14 (unch), NERV: 4.68 (+0.09), NLNK: 38.84 (+1.51), CPLA: 65.23 (-1.37), WYY: 1.50 (+0.02), ESP: 29.25 (+2.53)
New commercial chief at Catalyst Pharma
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:03PM CST
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
GlobeNewswire - Mon Jan 05, 7:25AM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that David D. Muth, currently Executive Vice President, Corporate Development of Catalyst, has been promoted to the newly created position of Executive Vice President, Chief Commercial Officer, effective January 1, 2015. Mr. Muth will continue to report to Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst.
CPRX: 3.36 (-0.10)
OTC Daily Alert Stock Watch - Catalyst Pharmaceuticals (NASDAQ: CPRX)
WorldStockWire - Mon Dec 29, 3:15PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CPRX: 3.36 (-0.10)
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Catalyst Pharmaceutical Partners, Inc. -- CPRX
GlobeNewswire - Thu Dec 18, 7:10AM CST
The Rosen Law Firm, P.A. announces that the United States District Court Southern District of Florida has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX):
CPRX: 3.36 (-0.10)
Catalyst Pharma founder passes
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:54AM CST
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals expresses sympathy on passing of co-founder and director Dr Hubert E. Huckel
M2 - Wed Dec 17, 7:59AM CST
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday that its co-founder and director Dr Hubert E. Huckel, MD has died.
CPRX: 3.36 (-0.10)
Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founder and Director
GlobeNewswire - Tue Dec 16, 2:45PM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced with great sadness the loss of Co-Founder and director, Hubert E. Huckel, M.D. Dr. Huckel, a founding shareholder and director of Catalyst since its formation in January 2002, passed away on December 13, 2014.
CPRX: 3.36 (-0.10)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 37.22 (+0.27), TNXP: 5.78 (-0.02), MRNS: 10.94 (-0.06), CPRX: 3.36 (-0.10), VNDA: 12.37 (unch), ITCI: 24.53 (+2.45), OMER: 20.63 (+0.13)
